To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Exclusion Criteria

• •Metaplastic breast cancer
• •History of leptomeningeal disease
• •Type 1 or 2 diabetes requiring anti-hyperglycemic medication
• •Inability or unwillingness to swallow pills
• •Malabsorption syndrome or other condition that would interfere with enteral absorption
• •Known and untreated, or active central nervous system metastases
• •Uncontrolled pleural effusion or ascites
• •Any active infection that could impact patient safety or serious infection requiring intravenous antibiotics
• •History of other malignancy within 5 years, except for treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer
• •History of or active ventricular dysrhythmias or congestive heart failure requiring medication or symptomatic coronary heart disease
• •Congenital long QT syndrome, prolonged QT interval, or family history of sudden unexplained death or long QT syndrome
• •Stage II Arms B, C, D, and E only:
• •Prior treatment with \>1 chemotherapy regimen for metastatic disease
• •Prior treatment with PI3K inhibitor
• •History of significant toxicity related to mTOR inhibitor requiring treatment discontinuation
• •Stage II Arms B and E only:
• •\- Prior CDK4/6 inhibitor treatment
• •Stage II Arm G only:
• •Current uncontrolled hypertension or unstable angina
• •History of congestive heart failure, serious cardiac arrhythmia, or recent myocardial infarction
• •Prior ejection fraction decrease on trastuzumab
• •Prior cumulative doxorubicin greater than 360 mg/m2
• •Symptomatic active lung disease
• •History of significant toxicity related to trastuzumab and/or pertuzumab requiring discontinuation of treatment